Vertex Pharmaceuticals shares fell 14% in post-market trading Monday after the company said it will not advance its ...

Wedbush analyst Dan Ives raised his price target on Palantir to $200, citing "hyper growth demand" and rapid commercial expansion. In a post on X, Ives called Palantir a key player in the "use case ...